hema.to is an easy-to-use clinical decision-making assistance software for patients with blood cancers that is based on cytometry data and uses AI. hema.to accelerates and improves the diagnostic workflow, helping both the diagnostician and the patient. hema.to is CE-IVD and FDA-registered and is already routinely used by leading hematology laboratories. Founded in 2021, hema.to's mission is to fully objectify the clinical analysis of cytometry data so that physicians can tailor treatment to their patients' individual immune systems.
